Vineet Laboratories Ltd

VINEETLABPharmaceuticals
33.02+0.00 (+0.00%)
As on 29 Jan 2026, 10:34 amMarket Open

Fundamental Score

...

Vineet Laboratories Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

-89.47%
Poor

Return on Capital Employed

-27.95%
Poor

Operating Profit Margin (5Y)

2.28%
Poor

Dividend Yield

0.00%

Valuation Metrics

Price to Earnings

N/A

Market Capitalization

39.25 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

121.86%
Poor

YoY Quarterly Sales Growth

-8.12%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Poor

Debt to Equity

3.01x
Poor

Interest Coverage

-2.75x
Good

Free Cash Flow (5Y)

18.91 (Cr)

Ownership Structure

Poor

Promoter Holding

15.89%
Poor

FII Holding

0.00%
Poor

DII Holding

0.00%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
15.89%
Promoter Holding
39.25 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of VINEETLAB across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Robust Profit Growth (121.86%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

12 factors identified

Below-Average Return on Equity (-89.47%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-27.95%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.

Margin Pressure Concerns (2.28%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.

Revenue Contraction (-8.12%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.

Elevated Debt Levels (D/E: 3.01)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.

Weak Interest Coverage (-2.75x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.

Low Promoter Commitment (15.89%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High Debt-to-Equity Ratio

Observation: Elevated financial risk due to high leverage.

Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.

Very High Debt Levels

Observation: Excessive leverage may strain cash flows.

Analysis: Debt-to-equity above 2.0 indicates potential financial distress risk.

Very Low ROE

Observation: Poor capital utilization and shareholder returns.

Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Financial Statements

Comprehensive financial data for Vineet Laboratories Ltd

About VINEETLAB

Business Overview

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.

Company Details

Symbol:VINEETLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Gaddam Venkata Ramana
Founder, MD & Director
Mr. Satyanarayana Raju Bhupathiraju
CFO & Whole-time Director
B V Ramakrishna
Senior Manager of Finance & Accounts

Corporate Events

Recent
Ex-Dividend Date
2022-09-19

VINEETLAB Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)-89.47%
Return on Capital Employed-27.95%
Operating Profit Margin (5Y)2.28%
Debt to Equity Ratio3.01
Interest Coverage Ratio-2.75

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth121.86%
YoY Quarterly Sales Growth-8.12%

Frequently Asked Questions

What is the current price of Vineet Laboratories Ltd (VINEETLAB)?

As of 29 Jan 2026, 10:34 am IST, Vineet Laboratories Ltd (VINEETLAB) is currently trading at ₹33.02. The stock has a market capitalization of ₹39.25 (Cr).

Is VINEETLAB share price Overvalued or Undervalued?

VINEETLAB is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.

What factors affect the Vineet Laboratories Ltd share price?

Key factors influencing VINEETLAB's price include its quarterly earnings growth (Sales Growth: -8.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Vineet Laboratories Ltd a good stock for long-term investment?

Vineet Laboratories Ltd shows a 5-year Profit Growth of N/A% and an ROE of -89.47%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 3.01 before investing.

How does Vineet Laboratories Ltd compare with its industry peers?

Vineet Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare VINEETLAB's P/E of 0.00x and ROE of -89.47% against the industry averages to determine its competitive standing.

What is the P/E ratio of VINEETLAB and what does it mean?

VINEETLAB has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.

How is VINEETLAB performing according to Bull Run's analysis?

VINEETLAB has a Bull Run fundamental score of N/A/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does VINEETLAB belong to?

VINEETLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vineet Laboratories Ltd.

What is Return on Equity (ROE) and why is it important for VINEETLAB?

VINEETLAB has an ROE of -89.47%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Vineet Laboratories Ltd generates profits from shareholders' equity.

How is VINEETLAB's debt-to-equity ratio and what does it indicate?

VINEETLAB has a debt-to-equity ratio of 3.01, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.

What is VINEETLAB's dividend yield and is it a good dividend stock?

VINEETLAB offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has VINEETLAB grown over the past 5 years?

VINEETLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in VINEETLAB and why does it matter?

Promoters hold 15.89% of VINEETLAB shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is VINEETLAB's market capitalization category?

VINEETLAB has a market capitalization of ₹39 crores, placing it in the Small-cap category.

How volatile is VINEETLAB stock?

VINEETLAB has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for VINEETLAB?

VINEETLAB has a 52-week high of ₹N/A and low of ₹N/A.

What is VINEETLAB's operating profit margin trend?

VINEETLAB has a 5-year average Operating Profit Margin (OPM) of 2.28%, indicating the company's operational efficiency.

How is VINEETLAB's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of -8.12% and YoY Profit Growth of 121.86%.

What is the institutional holding pattern in VINEETLAB?

VINEETLAB has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.